Sanofi (SNY) and GlaxoSmithKline (GSK) To Surge Amid Receiving $2.1 Billion To Fight COVID-19. Here is Why

‘Operation Warp Speed’ initiative from Federal authorities is aiding reliable biotech companies like Vaxart and Moderna. The turn came to Sanofi (NASDAQ: SNY) and Glax (NYSE: GSK) that already received rewards from the UK government to speed up the development of the COVID-19 vaccine and preserve for its population only.

SNY and GSK are not penny stock since they have no negative EPS. However, there has been no significant volatility in the stocks. They may rise at least 10% soon because short term traders can’t afford huge volumes of them.

Related:  Grubhub's Stock (NYSE: GRUB) Climbs, Q1 2020 Risen Revenue, Gross Profit, Net Loss

Investors are to stay alert by adding the stocks to watchlist while reading news that can impact on stock movement.

Asan Abdiev

CEO and Editor in Chief. Living in the era of dynamic tech change Asan decided to stay tuned in changes that make any person find comfort and adapt to new devices. Furthermore, gaming became his passion for spending leisure time with his close ones. Although, he has a degree in Business Administration (majoring Finance) writing for technology and as well as finance has been one of the precious aspects of his life